Quality of life and clinical and functional manifestations of peripheral polyneuropathy in patients with multiple myeloma on the background of dynamic electroneurostimulation

The aim of this study was to investigate the dynamic of pain syndrome, condition of microcirculatory vessels and quality of life in patients with multiple myeloma complicated by peripheral polyneuropathy in patients receiving bortezomib. The study involved 106 patients separated into 3 groups: in the study group the standard chemotherapy was supplemented with course of dynamic electrical nerve stimulation (15 sessions), in the second group the treatment was carried out against the background of the impact of the placebo device, in the third group only the standard treatment was used. In first group, the severity of pain and polyneuropathy decreased by the end of therapy in 1.8 times, while in the second and third groups – in 1.3 and 1.2 times respectively. The positive changes of initially elevated pain threshold have been revealed, the value of which fell to the end of the observation period in first group by 24.4 %, while, as in the second and third – by 8.3 % and 8.1 %, respectively. In the patients of the first group the indexes of basal microcirculation improved into 1.4 times, values of vasomotor oscillations of micro vessels decreased in 1.7 fold and data of pressure pulse increased in 1.2 times. Whereas the significant changes have not been detected in comparison groups. Also, the treatment demonstrated the significant improvement in quality of life: the physical functioning index by SF-36 questionnaire increased in 1.5-fold compared with baseline values, and performance overall health and vitality increased by 1.7 and 1.5 times, respectively, which is significantly superior to those indicators in the control groups. Consequently, the inclusion of dynamic electroneurostimulation in the treatment of multiple myeloma patients reduces the severity of pain, lowers the threshold of pain sensitivity, improves microcirculation and quality of life, which allows continuing the specific chemotherapy.